A Case of Pregnancy Despite Infertility From Congenital Plasminogen Deficiency
January 6th 2021Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the details of a patient who had a successful pregnancy despite documented infertility due to congenital plasminogen deficiency.
New Data Reinforce Long-Term Benefit of Emicizumab for Patients With Hemophilia A
December 11th 2020The data presented at ASH 2020 build on results previously observed in the pivotal HAVEN clinical trial among adults, adolescents, and children with hemophilia A, with and without factor VIII inhibitors.
The Most Interesting Results from the RESET Clinical Trial
December 9th 2020In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.
Treatment of Acquired Hemophilia A with Rituximab and Emicizumab
December 9th 2020Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII (FVIII), and the disorder is understudied given its rarity and the lack of randomized prospective trials to guide therapy.
Updated Giroctocogene Fitelparvovec Study for Patients with Severe Hemophilia A
December 8th 2020The update outlines that all 5 patients in the high dose 3 x 1013 vg/kg cohort have had at least 1 year of follow-up and showed sustained factor VIII (FVIII) activity levels, with a group median FVIII activity of 56.9% and a group geometric mean FVIII activity of 70.4% via chromogenic assay from week 9 to 52.
The Significance of 3 New Patient Cases in Understanding Congenital Plasminogen Deficiency
December 7th 2020Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on 3 new patient cases from their presentation and the significance of these cases to their research.
Understanding Parallel Target Identification Efforts in the Induction of Fetal Hemoglobin
December 7th 2020Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what their parallel target identification efforts were able to identify, and how this identification was important in his research.